Mein Warenkorb

COL1A1

COL1A1 Produktliste

  • Attribut

    Protein (2)

  • Produktbibliothek

    Online (2)

  • Spezies

    Human (1)Mouse (1)

  • Etikett

    His Tag (2)

  • Marker

    Unconjugated (2)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
CO1-H5243
Human
HEK293
Human COL1A1 Protein, His Tag, low endotoxin (MALS verified)
In den Warenkorb legen
CO1-M5243
Mouse
HEK293
Mouse COL1A1 Protein, His Tag, low endotoxin (MALS verified)
In den Warenkorb legen
Gesamtmenge2
  • 1

COL1A1 Molekülhintergrund

Type I collagen is the most abundant structural protein of connective tissues such as skin, bone and tendon. It is synthesized as a procollagen molecule which is characterized by a 300 nm triple helical domain flanked by globular N- and C-terminal propeptides. The triple helical domain contains Gly-Xaa-Yaa triplets where Xaa and Yaa are frequently proline and hydroxyproline, respectively. The non-helical propeptides are removed by procollagen N- and C-proteinase activities so that the mature triple helices can self-assemble into collagen fibrils that provide tensile strength to tissues. Type I collagen is a heterotrimer that consists of two alpha 1(I) chains and one alpha 2(I) chain, although homotrimers consisting of three identical alpha 1(I) chains have also been described .

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
AT-02AT-02Phase 2 ClinicalAttralus IncImmunoglobulin Light-chain Amyloidosis; Amyloidosis
Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ImlifidaseMac-1ApprovedHansamed IncIdefirixEURejection of renal transplantationHansa Biopharma Ab2020-08-25Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic
Details
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns